Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months.
Back to Health Page
Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 monthsDoctors are hailing “amazing” trial results that show a new drug combination stopped lung cancer advancing for more than 40% longer than the standard treatment.Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8 million deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor. Continue reading...
Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months.
Back to Health Page 
